After a series of high-profile pledges to bring drug manufacturing back to the United States, we are beginning to see a clearer picture of what reshoring actually looks like. Tens of billions of dollars are being spent on new factories in the United States, but the investment is unlikely to immediately translate into increased domestic production.
On this week’s episode of “The Topline,” Fierce’s Eric Sagonowski speaks with Rosemary Coates, executive director of the Reshoring Institute, to unpack current trends and what’s next. Mr. Coates explains why the pharmaceutical industry is uniquely positioned to bring supply chains back to the United States and the challenges faced by companies trying to make that happen.
Learn more about this episode’s topics:
Visited 10 times, 1 visit(s) today
